Summary of Clinical Use

IC14 was in clinical development for sepsis and ALS but none of the trials are active. It was progressed for COVID-19 in 2020. Results from early stage studies in healthy subjects, LPS-challenged subjects and patients with sepsis were reported in 2003 [2]. As of March 2024 most clinical trials involving IC14 had been terminated or withdrawn. The FDA's designation of IC14 as an orphan drug for ALS (issued in January 2021) appeared to still be in place at that time.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT00042588	A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis	Phase 2 Interventional	ICOS Corporation
NCT04346277	Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)	Expanded Access	Implicit Bioscience
NCT04391309	IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19)	Phase 2 Interventional	Implicit Bioscience
NCT04488081	I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients	Phase 2 Interventional	QuantumLeap Healthcare Collaborative
NCT04309604	IC14 for ALS Patients Expanded Access	Expanded Access	Implicit Bioscience		3